Balancing benefits and risks in the era of biologics

被引：12

作者：

Adami, Giovanni ^{[1
]}

Saag, Kenneth G. ^{[2
]}

Chapurlat, Roland D. ^{[3
]}

Guanabens, Nuria ^{[4
]}

Haugeberg, Glenn ^{[5
]}

Lems, Willem F. ^{[6
]}

Matijevic, Radmila ^{[7
,8
]}

Peel, Nicola ^{[9
]}

Poddubnyy, Denis ^{[10
,11
]}

Geusens, Piet ^{[12
,13
]}

机构：

[1] Univ Verona, Rheumatol Unit, Pz Scuro 10, I-37135 Verona, Italy

[2] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA

[3] Univ Lyon, Hop E Herriot, INSERM UMR 1033, Lyon, France

[4] Univ Barcelona, Hosp Clin, Rheumatol Dept, CIBERehd,IDIBAPS, Barcelona, Spain

[5] Southern Hosp Trust, Div Rheumatol, Med Dept, Trondheim, Norway

[6] Locat VUmc, Amsterdam UMC, Amsterdam, Netherlands

[7] Univ Novi Sad, Fac Med, Novi Sad, Serbia

[8] Clin Ctr Vojvodina, Clin Orthoped Surg, Novi Sad, Serbia

[9] Northern Gen Hosp, Metab Bone Ctr, Sheffield, S Yorkshire, England

[10] Charite Univ Med Berlin, Dept Gastroenterol Infect Dis & Rheumatol, Berlin, Germany

[11] German Rheumatism Res Ctr, Epidemiol Unit, Berlin, Germany

[12] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands

[13] Hasselt Univ, Biomed Res Ctr, Agoralaan, Diepenbeek, Belgium

来源：

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE | 2019年 / 11卷

关键词：

benefit-risk ratio; biologics; denosumab; romosozumab; POSTMENOPAUSAL WOMEN; RHEUMATOID-ARTHRITIS; CERTOLIZUMAB PEGOL; ROMOSOZUMAB; PREVENTION; INFLIXIMAB; FRACTURES; DENOSUMAB; DISEASES; SAFETY;

D O I：

10.1177/1759720X19883973

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.

引用

页数：6

共 50 条

[1] Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease
Dulai, Parambir S.
Siegel, Corey A.
Dubinsky, Marla C.
INFLAMMATORY BOWEL DISEASES, 2013, 19 (13) : 2927 - 2936
[2] Balancing risks and benefits
Nature Reviews Cancer, 2013, 13 (2) : 81 - 81
[3] A New Era in Cervical Cancer Screening: Balancing the Risks and Benefits of Screening
Teoh, Deanna
JOURNAL OF WOMENS HEALTH, 2016, 25 (03) : 207 - 208
[4] Tamoxifen, balancing risks and benefits
Bergman, L
Benraadt, J
vanLeeuwen, FE
NETHERLANDS JOURNAL OF MEDICINE, 1996, 49 (06): : 228 - 234
[5] NSAIDs Balancing the Risks and Benefits
Gorczyca, Pamela
Manniello, Marina
Pisano, Michele
Avena-Woods, Carmela
US PHARMACIST, 2016, 41 (03) : 24 - 35
[6] Balancing the risks and benefits in AMD
Beaumont, PE
Kang, HK
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2005, 33 (01): : 108 - 110
[7] Balancing the Risks and Benefits of Rituximab
Linos, Eleni
JAMA INTERNAL MEDICINE, 2013, 173 (10) : 926 - 926
[8] ECT - BALANCING RISKS AND BENEFITS
BROWN, JH
BRITISH MEDICAL JOURNAL, 1980, 280 (6225): : 1228 - 1228
[9] Lithium: balancing risks and benefits
Cookson, J
BRITISH JOURNAL OF PSYCHIATRY, 1997, 171 : 120 - 124
[10] ECT - BALANCING RISKS AND BENEFITS
POND, D
BRITISH MEDICAL JOURNAL, 1980, 280 (6211): : 403 - 403

← 1 2 3 4 5 →